Completed EARLY_PHASE1 INTERVENTIONAL 3-arm NCT01100736

Role of Endothelin-A (ETA) and Endothelin-B (ETB) Receptors in the Vasodilatory Response to Endothelin-3 (ET-3)

Characterisation of the Role of ETA and ETB Receptors in Regulating Plasma ET-1 and the Vasodilator Response to ET-3 in Man

Sponsor: Encysive Pharmaceuticals

Conditions Pulmonary Arterial Hypertension Vasoconstriction Vasodilation

Interventions Bosentan Endothelin-3 Placebo Sitaxsentan

Updated 6 times since 2017 Last updated: Jul 20, 2015 Started: Jan 31, 2009 Primary completion: Sep 30, 2009 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Pulmonary Arterial Hypertension and Vasoconstriction and is currently completed. Encysive Pharmaceuticals leads this study, which shows 6 recorded versions since 2009 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed EARLY_PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed EARLY_PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed EARLY_PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed EARLY_PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed EARLY_PHASE1

Phase: Phase 0 → EARLY_PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed Phase 0

First recorded

Jan 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Encysive Pharmaceuticals
University of Edinburgh

Data source: University of Edinburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Edinburgh, United Kingdom